Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Beyond Medical Technologies Inc DOCKF


Primary Symbol: C.DOCT

Healthcare Cannabis
Beyond Medical Technologies Inc. is a Canada-based company. The Company has no business operations and has no revenue. The Company is seeking new business opportunities.


CSE:DOCT - Post by User

Beyond Medical Technologies Inc > The company states
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by Destro65on Dec 27, 2019 5:20pm
195 Views
Post# 30495496

RE:RE:RE:RE:RE:RE:RE:The company states

RE:RE:RE:RE:RE:RE:RE:The company statesFor yr 2018: Salaries and consulting = 170k Business development = 130k R&D = 13k For 2017: Salaries and consulting = $547k Business development = $271k R&D =$0 For 2016: Salaries and consulting = $216k Business development = $6k R&D = $0 In no year has salaries and consulting fees been less than R&D + business development. NEED I SAY MORE?
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities